Skip to main content

NanoDetection Technology Raises $2.3M in Series A Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NanoDetection Technology and CincyTech today announced that NDT has completed a Series A financing round raising $2.3 million.

The round was oversubscribed as NDT had targeted $2 million.

In total, 21 investors participated in the round. CincyTech led the round with an investment of $400,000 and brought in half a dozen investors into the deal, it and NDT said. Southern Ohio Creates Companies invested $100,000.

Proceeds from the Series A round are expected to fund its clinical trials and plans to get clearance from the US Food and Drug Administration for a test for Staphylococcus aureus. The test is expected to become available in late 2013.

NDT has developed a rapid and cost-effective point-of-care IVD test platform for the detection of pathogens including MRSA, E. coli, salmonella, and listeria, as well as for DNA and other biomarker-based tests, it and CincyTech said.

NDT had been based in Knoxville, Tenn., but moved to Cincinnati last fall. Joel Ivers became its CEO in July 2010.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.